Predict your next investment

Corporation
HEALTHCARE | Medical Devices & Equipment / Device Design & Manufacturing
sjm.com

See what CB Insights has to offer

Investments

13

Portfolio Exits

3

Partners & Customers

10

Service Providers

1

About St. Jude Medical

St. Jude Medical develops medical technology and services that focus on putting more control into the hands of those who treat cardiac, neurological, and chronic pain patients worldwide.

St. Jude Medical Headquarter Location

1 St. Jude Medical Dr

Saint Paul, Minnesota, 55117,

United States

651-756-2000

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing St. Jude Medical

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find St. Jude Medical in 2 Expert Collections, including Medical Devices.

M

Medical Devices

3,383 items

Companies that received PMA from the FDA since 2014. Companies tagged as #FDAPMA

D

Digital Health

12,256 items

Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)

Latest St. Jude Medical News

Colchicine fails to reduce mechanical ventilation, 28-day mortality in COVID-19 pneumonia

Jan 12, 2022

Disclosures: This study was funded by the Population Health Research Institute and Fundacion ECLA. Bhatt reports grants from Amarin, AstraZeneca, Forest Laboratories, Bristol Myers Squibb, Eisai, Ethicon, Medtronic, Sanofi Aventis, The Medicines Company, Roche, Pfizer, Ischemix, Cardax, Amgen, Eli Lilly & Co., Chiesi, Ironwood, PhaseBio, Idorsia, Synaptic, Abbott, Regeneron, Novo Nordisk, Fractyl, Cereno Scientific, Afimmune, Ferring Pharmaceuticals, Contego Medical, CellProthera, Lexicon, MyoKardia, Owkin, HLS Therapeutics, Janssen, 89Bio, Garmin, PLxPharma, and Novartis; personal fees from Duke Clinical Research Institute, the Mayo Clinic, the Population Health Research Institute, the American College of Cardiology, Belvoir Publications, Slack Publications, WebMD, Elsevier, the Society of Cardiovascular Patient Care, HMP Global, Harvard Clinical Research Institute, the Journal of the American College of Cardiology, the American Heart Association, the Cleveland Clinic, Mount Sinai School of Medicine, TobeSoft, Boehringer Ingelheim, Bayer, Medtelligence/ReachMD, CSL Behring, MJH Life Sciences, Level Ex, K2P, and the Canadian Medical and Surgical Knowledge Translation Research Group; serving as a site coinvestigator for Abbott, Biotronik, Boston Scientific, CSI, St. Jude Medical, Philips, and Svelte; performing unfunded research for FlowCo, Merck, and Takeda; serving on an advisory board for Medscape Cardiology and Regado Biosciences; serving as a deputy editor for Clinical Cardiology and on the publications committee for VA CART Research and Publications Committee; and serving on the board of directors for Boston VA Research Institute. Please see the study for all other authors’ relevant financial disclosures. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Please try again later. If you continue to have this issue please contact customerservice@slackinc.com . Back to Healio Colchicine fails to significantly reduce mechanical ventilation or 28-day mortality in hospitalized patients with COVID-19 pneumonia, compared with usual care, according to data published in JAMA Network Open. “Colchicine is a relatively safe, and in most parts of the world, inexpensive anti-inflammatory drug with which doctors everywhere are familiar,” Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC, of Brigham and Women’s Hospital and Harvard Medical School, in Boston, told Healio. “Those attributes of colchicine led to this trial in patients hospitalized with COVID-19. If it had been positive, it would have been an easy to implement therapy for COVID.” Colchicine fails to significantly reduce mechanical ventilation or 28-day mortality in hospitalized patients with COVID-19 pneumonia, compared with usual care, according to data derived from Diaz R, et al. JAMA Netw Open. 2021;doi:10.1001/jamanetworkopen.2021.41328. To analyze the efficacy of colchicine among hospitalized patients with COVID-19 pneumonia , Bhatt and colleagues conducted the COLOCOVID study, a multicenter, open-label, randomized clinical trial. A total of 1,279 adults hospitalized with confirmed or suspected COVID-19 — with severe acute respiratory syndrome characterized by shortness of breath or typical or atypical pneumonia on imaging, or oxygen desaturation — were randomized 1:1 to receive usual care or usual care plus colchicine. Patients with clear indications or contraindications for colchicine , chronic kidney disease or a negative reverse transcription-polymerase chain reaction test for COVID-19 prior to randomization were excluded. In all, 639 patients were assigned to the usual care group, while 640 patients received colchicine. Corticosteroids were used in 1,171 participants, or 91.5% of the total study population. Deepak L. Bhatt Colchicine was administered orally in a loading dose of 1.5 mg immediately after randomization, followed by a 0.5 mg dose within 2 hours of the initial dose and additional 0.5 mg doses twice a day for 14 days or discharge. The trial was conducted from April 17, 2020, to March 28, 2021. Participants were followed for 28 days, with analysis conducted from June 20, 2021, to July 25, 2021. Main outcomes included new requirement for mechanical ventilation or death evaluated at 28 days, with death at 28 days serving as a second coprimary outcome. According to the researchers, mechanical ventilation or 28-day death occurred in 25% of patients in the colchicine group, compared with 28.8% in the usual care group (HR = 0.83; 95% CI, 0.67-1.02). Meanwhile, the second coprimary outcome, 28-day death, occurred in 20.5% of those who received colchicine, compared with 22.2% in those who received usual care (HR = 0.88; 95% CI, 0.7-1.12). Diarrhea was the most frequent adverse effect of colchicine, reported in 11.3% of patients in the group. “The data from this trial do not show any significant benefit of colchicine in COVID-19 patients, and the drug should not be used for that purpose at this time without further larger, definitive randomized trials that show clear benefit,” Bhatt said. “There appeared to be a possible signal of a modest degree of benefit that would need to be confirmed in a larger, adequately sized trial of either colchicine or maybe other drugs that have anti-inflammatory effects but have been repurposed for potential use in COVID-19 patients,” he added. “Hopefully, such trials will occur, but it may be challenging to find funding to conduct trials that are large enough to be definitive.” Read more about

St. Jude Medical Investments

13 Investments

St. Jude Medical has made 13 investments. Their latest investment was in Spinal Modulation as part of their Corporate Minority on June 6, 2013.

CBI Logo

St. Jude Medical Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

6/11/2013

Corporate Minority

Spinal Modulation

$40M

Yes

2

5/6/2011

Series C

iRhythm Technologies

$15M

No

9/17/2010

Corporate Minority

CardioMems

$60M

No

1

5/21/2010

Series B

Subscribe to see more

$99M

Subscribe to see more

0

5/19/2010

Series G

Subscribe to see more

$99M

Subscribe to see more

0

Date

6/11/2013

5/6/2011

9/17/2010

5/21/2010

5/19/2010

Round

Corporate Minority

Series C

Corporate Minority

Series B

Series G

Company

Spinal Modulation

iRhythm Technologies

CardioMems

Subscribe to see more

Subscribe to see more

Amount

$40M

$15M

$60M

$99M

$99M

New?

Yes

No

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

2

1

0

0

St. Jude Medical Portfolio Exits

3 Portfolio Exits

St. Jude Medical has 3 portfolio exits. Their latest portfolio exit was iRhythm Technologies on October 20, 2016.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

10/20/2016

IPO

$99M

12

10/19/2016

Divestiture

Subscribe to see more

Subscribe to see more

10

11/14/2007

Acquired

Subscribe to see more

$99M

Subscribe to see more

0

Date

10/20/2016

10/19/2016

11/14/2007

Exit

IPO

Divestiture

Acquired

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Sources

12

10

0

St. Jude Medical Acquisitions

14 Acquisitions

St. Jude Medical acquired 14 companies. Their latest acquisition was Thoratec on July 22, 2015.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

7/22/2015

$99M

Acq - P2P

1

4/20/2015

Other

$99M

$106.9M

Acquired

1

8/7/2014

$99M

Acquired

2

6/2/2014

Other

Subscribe to see more

$99M

$99M

Subscribe to see more

10

10/15/2013

Series C

Subscribe to see more

$99M

$99M

Subscribe to see more

10

Date

7/22/2015

4/20/2015

8/7/2014

6/2/2014

10/15/2013

Investment Stage

Other

Other

Series C

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Total Funding

$106.9M

$99M

$99M

Note

Acq - P2P

Acquired

Acquired

Subscribe to see more

Subscribe to see more

Sources

1

1

2

10

10

St. Jude Medical Partners & Customers

10 Partners and customers

St. Jude Medical has 10 strategic partners and customers. St. Jude Medical recently partnered with World Health Organization on September 9, 2018.

Date

Type

Business Partner

Country

News Snippet

Sources

9/27/2018

Partner

World Health Organization

Switzerland

World Health Organization, St. Jude Children's Research Hospital collaborate against childhood...

MEMPHIS , Tenn. , Sept. 27 , 2018 / PRNewswire / -- St. Jude today announced a five-year collaboration with World Health Organization aimed at transforming cancer care worldwide to cure at least 60 percent of children with six of the most common types of cancer by 2030 .

2

6/5/2018

Partner

Destination XL Group

United States

1

12/18/2017

Partner

National Beverage

United States

National Beverage Reveres the Kids of St. Jude

FORT LAUDERDALE , Fla. -- -- National Beverage is commemorating its 24th year as a continuing partner of St. Jude ® by asking all to join its mission to supply hope for children stricken with life-threatening diseases .

1

11/21/2017

Partner

Brinker International

United States

Subscribe to see more

Subscribe to see more

10

7/5/2017

Partner

New York & Company

United States

Subscribe to see more

Subscribe to see more

10

Date

9/27/2018

6/5/2018

12/18/2017

11/21/2017

7/5/2017

Type

Partner

Partner

Partner

Partner

Partner

Business Partner

World Health Organization

Destination XL Group

National Beverage

Brinker International

New York & Company

Country

Switzerland

United States

United States

United States

United States

News Snippet

World Health Organization, St. Jude Children's Research Hospital collaborate against childhood...

MEMPHIS , Tenn. , Sept. 27 , 2018 / PRNewswire / -- St. Jude today announced a five-year collaboration with World Health Organization aimed at transforming cancer care worldwide to cure at least 60 percent of children with six of the most common types of cancer by 2030 .

National Beverage Reveres the Kids of St. Jude

FORT LAUDERDALE , Fla. -- -- National Beverage is commemorating its 24th year as a continuing partner of St. Jude ® by asking all to join its mission to supply hope for children stricken with life-threatening diseases .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

2

1

1

10

10

St. Jude Medical Service Providers

1 Service Provider

St. Jude Medical has 1 service provider relationship

Service Provider

Associated Rounds

Provider Type

Service Type

Acq - P2P

Investment Bank

Sole Financial Advisor

Service Provider

Associated Rounds

Acq - P2P

Provider Type

Investment Bank

Service Type

Sole Financial Advisor

Partnership data by VentureSource

St. Jude Medical Team

16 Team Members

St. Jude Medical has 16 team members, including current Executive Vice President, Kenneth Hawari.

Name

Work History

Title

Status

Kenneth Hawari

Executive Vice President

Current

Paul Buckman

President

Former

James Dennis

President

Former

Eric S Fain

President, Executive Vice President, Senior Vice President

Former

George J Fazio

President

Former

Name

Kenneth Hawari

Paul Buckman

James Dennis

Eric S Fain

George J Fazio

Work History

Title

Executive Vice President

President

President

President, Executive Vice President, Senior Vice President

President

Status

Current

Former

Former

Former

Former

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.